Neuroprotective properties of dehydroepiandrosterone-sulfate and its relationship to interleukin 6 after aneurysmal subarachnoid hemorrhage: a prospective cohort study

Table 4 DHEAS levels during the inpatient stay according to functional outcome 6 months after aneurysmal subarachnoid hemorrhage (dichotomized modified Rankin scale score)

	Minimum	Maximum	Mean	SD	95 % CI	Number
DHEAS day 0
Favorable	<150	5260	1411	1161	1000, 1823	33
Unfavorable	<150	2310	1052	678	766, 1338	24
DHEAS day 1
Favorable	<150	4460	1135	1035	768, 1502	33
Unfavorable	<150	2740	820	609	563, 1077	24
DHEAS day 4
Favorable	<150	2840	699	700	451, 948	33
Unfavorable	<150	1700	515	497	283, 748	20
DHEAS day 7
Favorable	<150	3780	770	838	467, 1072	32
Unfavorable	<150	1110	339	324	187, 491	20
DHEAS day 10
Favorable	155	5770	982	1251	523, 1441	31
Unfavorable	<150	776	255	249	127, 383	17
DHEAS day 14
Favorable	<150	2560	669	604	435, 903	28
Unfavorable	<150	1090	359	342	153, 566	13

Dehydroepiandrosterone-sulfate (DHEAS) levels (ng/ml) during acute stage of disease according to dichotomized (Favorable vs Unfavorable) outcome 6 months after aneurysmal subarachnoid hemorrhage. Number number of cases analyzed

ISSN: 1364-8535